Page 130 - EJMO-9-3

Eurasian Journal of Medicine

and Oncology

ORIGINAL RESEARCH ARTICLE
Meta-analysis of the prognostic value of KRAS

and TP53 mutations in cholangiocarcinoma

Benfeng Xu, Chuhan Zhang, Yibin Zhou, and Jianan Jin*
Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China

Abstract
Introduction: KRAS and TP53 mutations are among the most common genetic
mutations in cholangiocarcinoma.
Objective: This study aimed to explore the potential impact of these mutations on
the survival prognosis of cholangiocarcinoma patients through a meta-analysis.
Methods: A systematic search was conducted in PubMed, Web of Science, Cochrane
Library, Embase, CNKI, and Wanfang databases for cohort studies published up to April
2025 that investigated the relationship between KRAS and TP53 mutations and patient
prognosis. Two researchers independently performed the literature screening and
data extraction. Meta-analysis was conducted using RevMan 5.4 and Stata 17.0, with
assessment of publication bias.
Results: Twelve studies were included, involving a total of 1,126 patients, with 167
cases of KRAS mutations and 176 cases of TP53 mutations. The results showed that both
KRAS and TP53 mutations were significantly associated with poorer survival prognosis
*Corresponding author: in cholangiocarcinoma patients. For KRAS (hazard ratio (HR)=7.26; 95% confidence
Jianan Jin
(915683117@qq.com) interval (CI): 6.10 – 9.81; p<0.05) and TP53 (HR=18.13; 95% CI: 11.24 – 25.32; p<0.05), the
presence of mutations predicted an adverse prognosis.
Citation: Xu B, Zhang C, Zhou Y, Conclusion: While these findings suggest that KRAS and TP53 mutations are associated
Jin J. Meta-analysis of the
prognostic value of KRAS and TP53 with worse survival in cholangiocarcinoma, the limited number and quality of the
mutations in cholangiocarcinom. included studies warrant further high-quality research to validate these associations.
Eurasian J Med Oncol.
2025;9(3):122-132.
doi: 10.36922/EJMO025120063 Keywords: Cholangiocarcinoma; KRAS mutation; TP53 mutation; Prognosis; Meta-
Received: March 22, 2025 analysis; Cohort studies
Revised: April 10, 2025
Accepted: May 6, 2025 1. Introduction
Published online: May 22, 2025 Cholangiocarcinoma, a malignant tumor of the bile duct, can be anatomically classified
Copyright: © 2025 Author(s). into intrahepatic and extrahepatic types. It currently accounts for approximately 3%
This is an Open-Access article of all gastrointestinal cancers. In recent years, the incidence and mortality rates of
1
distributed under the terms of the
2
Creative Commons Attribution cholangiocarcinoma have been rising globally, particularly in Asia. The primary treatment
License, permitting distribution, for early-stage cholangiocarcinoma is surgical resection; however, due to non-specific
and reproduction in any medium, symptoms and subtle clinical manifestations in the early stages, 50 – 60% of patients are
provided the original work is
3
properly cited. diagnosed at an advanced stage, with surgery suitable for only 15% of these cases. Current
research shows that the 5-year survival rate for advanced cholangiocarcinoma is extremely
Publisher’s Note: AccScience
Publishing remains neutral with low, making early diagnosis and prognostic assessment critical for clinical decision-making. 4
regard to jurisdictional claims in
published maps and institutional KRAS and TP53 mutations are significant molecular biomarkers in cancer development
5-7
affiliations. and have been extensively studied for their prognostic relevance. The Ras gene family is
Volume 9 Issue 3 (2025) 122 doi: 10.36922/EJMO025120063